

NOT FOR PUBLICATIONIN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY
CAMDEN VICINAGEJANSSEN PHARMACEUTICALS, INC.
et al.

Plaintiffs,

v.

ALKEM LABORATORIES, LTD. *et al.*

Defendants.

HONORABLE KAREN M. WILLIAMS

Civil Action

No. 1:23-cv-2939 (KMW-SAK)

**FINAL JUDGMENT ORDER
FILED UNDER SEAL**

THIS MATTER having come to trial before the Court, Honorable Karen M. Williams, District Judge presiding, the issues having been heard and a decision having been rendered, for the reasons set forth in the Opinion of even date:

IT IS this 28th day of August, 2026, **HEREBY ORDERED AND ADJUDGED** as follows:


- A.** Judgment is entered in favor of Plaintiffs Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV (collectively “Janssen” or “Plaintiffs”) and against Defendant Sandoz, Inc.¹ (“Defendant” or “Sandoz”) on all of Plaintiffs’ claims (ECF No. 1, Counts I-IV) and Sandoz’s counterclaims (ECF No. 14, Counts I-VIII), with respect to claims 4, 16, 23, and 29 of U.S. Patent No. 10,869,844 (“844 Patent”), claim 10 of U.S. Patent No. 11,173,134 (“134 Patent”), claims 6, 16, and 18 of U.S. Patent No. 11,311,500 (“500 Patent”), and claims 22 and 36 of U.S. Patent No. 11,446,260 (“260 Patent” or the “Basstanie Patent”).
- B.** Claims 4, 16, 23, and 29 of the 844 Patent, claim 10 of the 134 Patent, claims 6, 16, and 18 of the 500 Patent, and claims 22 and 36 of the 260 Patent are infringed, and not invalid.

¹ Janssen filed a Complaint against Sandoz in 1:23-cv-2943-KMW-SAK. On October 6, 2023, the case was consolidated and this Action No., 23-cv-2939, was designated as the lead action. Accordingly, while all future filings were filed in this action, any filing prior to October 6, 2023 refers to the original Action No., 23-cv-2943.

- C. By submitting Abbreviated New Drug Application (“ANDA”) No. 215418 seeking approval to engage in the commercial manufacture, use, sale, and/or importation of generic esketamine nasal spray products for the treatment of certain forms of depression within the United States (“Sandoz’s ANDA Product”), Sandoz has infringed claims 4, 16, 23, and 29 of the 844 Patent, claim 10 of the 134 Patent, claims 6, 16, and 18 of the 500 Patent, and claims 22 and 36 of the 260 Patent.
- D. If Sandoz commercially manufactures, uses, markets, offers to sell, or sells Sandoz’s ANDA Product within the United States, or imports Sandoz’s ANDA Product into the United States prior to the expiration of ‘844, ‘134, ‘500 patents (September 14, 2035), and the 260 patent (March 14, 2034), Sandoz will infringe claims 4, 16, 23, and 29 of the 844 Patent, claim 10 of the 134 Patent, claims 6, 16, and 18 of the 500 Patent, and claims 22 and 36 of the 260 Patent.
- E. For as long as claims 4, 16, 23, and 29 of the 844 Patent, claim 10 of the 134 Patent, claims 6, 16, and 18 of the 500 Patent, and claims 22 and 36 of the 260 Patent remain extant and enforceable, pursuant to 35 U.S.C. § 271(c)(4)(A), the Food and Drug Administration (“FDA”) cannot finally approve ANDA No. 215418 earlier than the latest date of expiration of the Patents-in-Suit.
- F. For as long as claims as claims 4, 16, 23, and 29 of the 844 Patent, claim 10 of the 134 Patent, claims 6, 16, and 18 of the 500 Patent, and claims 22 and 36 of the 260 Patent remain extant and enforceable Sandoz and its officers, agents, servants, employees, and attorneys, and those persons in active concert or participation with them, as well as any successors and/or assignees of ANDA No. 215418, are hereby enjoined from manufacturing, using, offering to sell, or selling within the United States, or importing into the United States, Sandoz’s Anda Products until the latest expiration of the Patents-in-Suit, except to the extent subsequently (a) agreed between the Parties or (b) ordered or otherwise permitted by this Court or other tribunal with proper authority. This injunction order is effective immediately.
- G. Pursuant to Rule 54(d) of the Federal Rules of Civil Procedure and 28 U.S.C. 1920, Plaintiffs are the prevailing parties and shall recover their costs from Defendants.
- H. The Clerk of Court shall file this Order and Opinion under temporary seal.
- I. To the extent that the parties seek to redact portions of this Opinion and Order, within thirty (30) days of the entry of the Order, counsel shall file a single, consolidated motion to seal pursuant to L.Civ.R. 5.3(c)(3), addressing the applicable factors set

forth therein; including an index substantially in the form suggested by Appendix U;
and including Proposed Findings of Fact and Conclusions of Law.

- J.** The Clerk's Office is instructed to mark this matter **CLOSED**.
- K.** The Clerk's Office is instructed to email lead counsel for all parties the sealed Order and Opinion.



KAREN M. WILLIAMS
United States District Judge